MNKD
MannKind Corporation
$3.52
-0.85%
2026-05-08
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Key Fundamentals
P/E Ratio
30.55
Forward P/E
18.83
EPS (TTM)
$-0.07
Revenue Growth (YoY)
15.1%
Profit Margin
-6.6%
Beta
1.04
Market Cap
$1.12B
Avg Volume (10D)
8.1M
Recent Breakout Signals
No recent breakout signals detected for MNKD.
Recent Price Range (60 Days)
60D High
$5.77
60D Low
$2.23
Avg Volume
6.4M
Latest Close
$3.52
Get breakout alerts for MNKD
Sign up for Breakout Scanner to receive daily notifications when MNKD triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
MannKind Corporation (MNKD) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MNKD daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MNKD operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.